VTRS Viatris Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1792044 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.3%
TTM net income YoY—
TTM EPS YoY83.1%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-0.0%
Net margin—
FCF margin14.3%
EBITDA margin19.1%
Returns
ROE—
ROA—
ROIC (approx.)-0.0%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets60.5%
Debt / equity0.97x
Current ratio1.55x
Interest coverage-0.01x
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.75B | $3.76B | $3.52B | $3.70B | $3.76B | $3.58B | $3.25B | $3.53B |
| Cost of revenue | $2.31B | $2.30B | $2.36B | $2.56B | $2.39B | $2.25B | $2.09B | $2.31B |
| Gross profit | $1.44B | $1.46B | $1.16B | $1.15B | $1.37B | $1.33B | $1.16B | $1.22B |
| R&D expense | $231.70M | $248.30M | $248.60M | $274.70M | $250.40M | $218.80M | $222.00M | $206.50M |
| SG&A expense | $950.80M | $1.13B | $928.80M | $1.03B | $886.60M | $928.70M | $948.10M | $1.05B |
| Operating income | $261.50M | $6.30M | -$79.70M | -$192.70M | $178.80M | $233.00M | -$2.88B | -$179.80M |
| Interest expense | $112.40M | $120.70M | $120.10M | $119.60M | $119.60M | $116.60M | $115.50M | $120.20M |
| Pretax income | $127.90M | -$64.00M | -$247.30M | -$343.00M | -$7.90M | -$217.10M | -$3.10B | -$526.50M |
| Income tax | $453.20M | $54.80M | -$423.70M | -$2.90M | $120.30M | -$212.50M | -$55.00M | -$10.00M |
| Net income | -$325.30M | -$118.80M | $176.40M | — | -$128.20M | -$4.60M | -$3.04B | — |
| EBITDA | $958.70M | $678.60M | $596.40M | $574.10M | $867.30M | $911.30M | -$2.22B | $566.40M |
| EPS (basic) | -0.28 | -0.10 | 0.15 | — | -0.11 | 0.00 | -2.55 | — |
| EPS (diluted) | -0.28 | -0.10 | 0.15 | — | -0.11 | 0.00 | -2.55 | — |
| Dividends declared per share | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| Weighted avg. shares (diluted) | 1.15B | 1.16B | 1.18B | — | 1.16B | 1.17B | 1.19B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.79B | $886.50M | $1.80B | $1.32B | $975.30M | $566.40M | $755.00M | $736.10M |
| Short-term investments | — | — | — | $40.70M | — | — | — | $38.00M |
| Receivables | $3.12B | $3.13B | $3.08B | $3.03B | $3.37B | $3.26B | $3.13B | $3.22B |
| Inventory | $3.83B | $3.93B | $3.93B | $4.00B | $4.11B | $4.26B | $4.10B | $3.85B |
| Current assets | $10.30B | $10.06B | $10.92B | $9.79B | $9.95B | $9.77B | $9.62B | $9.52B |
| PP&E, net | $2.42B | $2.44B | $2.53B | $2.61B | $2.63B | $2.64B | $2.64B | $2.67B |
| Goodwill | $6.62B | $6.65B | $6.69B | $6.75B | $6.73B | $6.75B | $6.46B | $9.13B |
| Intangibles | $13.08B | $13.68B | $14.48B | $15.10B | $15.72B | $16.32B | $16.66B | $17.07B |
| Total assets | $34.68B | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B |
| Current liabilities | $6.64B | $6.35B | $6.81B | $7.09B | $7.36B | $7.13B | $5.72B | $5.78B |
| Short-term debt | $1.72B | $1.74B | $1.93B | $1.93B | $1.94B | $1.67B | $700,000 | $600,000 |
| Long-term debt | $11.59B | $11.61B | $12.41B | $12.48B | $12.49B | $12.79B | $14.18B | $14.04B |
| Total debt | $13.31B | $13.35B | $14.34B | $14.41B | $14.43B | $14.46B | $14.18B | $14.04B |
| Total liabilities | $21.00B | $20.78B | $22.18B | $22.48B | $22.70B | $22.84B | $22.82B | $22.87B |
| Shareholders' equity | $13.69B | $14.26B | $14.66B | $14.71B | $15.22B | $15.57B | $15.65B | $18.64B |
| Net debt | $11.52B | $12.46B | $12.54B | $13.09B | $13.46B | $13.90B | $13.42B | $13.30B |
| Cash flow statement | ||||||||
| Operating cash flow | $899.40M | $381.80M | $388.30M | $815.80M | $744.90M | $219.70M | $535.50M | $482.70M |
| Capital expenditure | $85.70M | $52.80M | $39.90M | $196.50M | $86.80M | $52.90M | $42.60M | $140.40M |
| Free cash flow | $813.70M | $329.00M | $348.40M | $619.30M | $658.10M | $166.80M | $492.90M | $342.30M |
| Investing cash flow | $292.30M | -$51.60M | $277.40M | -$211.20M | -$98.90M | -$52.50M | -$65.10M | -$168.70M |
| Financing cash flow | -$289.80M | -$1.24B | -$203.80M | -$236.40M | -$228.10M | -$362.40M | -$467.00M | -$1.42B |
| Depreciation & amortization | $697.20M | $672.30M | $676.10M | $766.80M | $688.50M | $678.30M | $664.70M | $746.20M |
| Stock-based compensation | $39.60M | $38.70M | $48.20M | $49.40M | $36.00M | $37.10M | $55.20M | $32.30M |
| Share buybacks | $150.00M | $150.00M | $0 | $85.10M | $67.90M | $175.00M | $175.40M | $0 |
Free plan shows the latest 8 periods; Pro shows all 32 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.